日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer

活细胞侵袭性表型分析揭示 ALK2 是 LKB1 突变型肺癌的治疗靶点

Junghui Koo, Chang-Soo Seong, Rebecca E Parker, Amy Herrera, Bhakti Dwivedi, Robert A Arthur, Ashok Reddy Dinasarapu, Henry Richard Johnston, Henry Claussen, Carol Tucker-Burden, Suresh S Ramalingam, Haian Fu, Wei Zhou, Adam I Marcus #, Melissa Gilbert-Ross #

Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981

肿瘤内YAP和TAZ异质性驱动非小细胞肺癌的集体侵袭,而SUMO化抑制剂TAK-981正是针对这种侵袭。

Richa Sharma ,Shagun Sharma ,Pratik Shriwas ,Labdhi Mehta ,An H Vu ,Janna K Mouw ,Junghui Koo ,Chunzi Huang ,Veronika Y Matsuk ,Carol Tucker-Burden ,Gregory Joseph ,Madhusmita Behera ,Shi-Yong Sun ,Melissa A Roy ,Melissa Gilbert-Ross ,Ticiana Leal ,Adam I Marcus ,Mala Shanmugam

Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer

活细胞侵袭性表型分析揭示 ALK2/BMP6 铁稳态通路是 LKB1 突变型肺癌治疗的一个弱点

Junghui Koo, Chang-Soo Seong, Rebecca E Parker, Bhakti Dwivedi, Robert A Arthur, Ashok Reddy Dinasarapu, H Richard Johnston, Henry Claussen, Carol Tucker-Burden, Suresh S Ramalingam, Haian Fu, Wei Zhou, Adam I Marcus, Melissa Gilbert-Ross

Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis

内吞肿瘤抑制因子HD-PTP的缺失会模拟LKB1的表型,并促进RAS驱动的肿瘤发生。

Seong, Chang-Soo; Huang, Chunzi; Boese, Austin C; Hou, Yuning; Koo, Junghui; Mouw, Janna K; Rupji, Manali; Joseph, Greg; Johnston, H Richard; Claussen, Henry; Switchenko, Jeffrey M; Behera, Madhusmita; Churchman, Michelle; Kolesar, Jill M; Arnold, Susanne M; Kerrigan, Katie; Akerley, Wallace; Colman, Howard; Johns, Margaret A; Arciero, Cletus; Zhou, Wei; Marcus, Adam I; Ramalingam, Suresh S; Fu, Haian; Gilbert-Ross, Melissa

Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth

更正:GSK3 是雷帕霉素类似物诱导某些致癌蛋白降解和抑制癌细胞生长所必需的。

Koo, Junghui; Wang, Xuerong; Owonikoko, Taofeek K; Ramalingam, Suresh S; Khuri, Fadlo R; Sun, Shi-Yong

Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma

靶向 KRAS、LKB1 突变肺腺癌中的粘附信号

Melissa Gilbert-Ross, Jessica Konen, Junghui Koo, John Shupe, Brian S Robinson, Walter Guy Wiles 4th, Chunzi Huang, W David Martin, Madhusmita Behera, Geoffrey H Smith, Charles E Hill, Michael R Rossi, Gabriel L Sica, Manali Rupji, Zhengjia Chen, Jeanne Kowalski, Andrea L Kasinski, Suresh S Ramaling

Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.

Rictor 经历糖原合成酶激酶 3 (GSK3) 依赖性、FBXW7 介导的泛素化和蛋白酶体降解

Koo Junghui, Wu Xiaoyun, Mao Zixu, Khuri Fadlo R, Sun Shi-Yong

mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation

mTOR 复合物 2 通过抑制糖原合酶激酶 3 依赖性和 SCF-FBXW7 介导的降解来稳定 Mcl-1 蛋白

Junghui Koo, Ping Yue, Xingming Deng, Fadlo R Khuri, Shi-Yong Sun

Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth

维持糖原合酶激酶 3 活性对于 mTOR 激酶抑制剂抑制癌细胞生长至关重要

Junghui Koo, Ping Yue, Anthony A Gal, Fadlo R Khuri, Shi-Yong Sun

The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis

E3 泛素连接酶 β-TrCP 和 FBXW7 协同介导 Akt 抑制剂 API-1 诱导的 GSK3 依赖性 Mcl-1 降解,导致细胞凋亡

Hui Ren, Junghui Koo, Baoxiang Guan, Ping Yue, Xingming Deng, Mingwei Chen, Fadlo R Khuri, Shi-Yong Sun